Candel Therapeutics (NASDAQ:CADL) CTO Sells $70,140.00 in Stock

Candel Therapeutics, Inc. (NASDAQ:CADL) CTO Seshu Tyagarajan sold 7,000 shares of the business’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $10.02, for a total value of $70,140.00. Following the completion of the sale, the chief technology officer owned 83,865 shares in the company, valued at approximately $840,327.30. The trade was a 7.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Candel Therapeutics Price Performance

Shares of NASDAQ CADL opened at $9.83 on Friday. The company has a debt-to-equity ratio of 0.34, a current ratio of 28.05 and a quick ratio of 28.05. The stock has a market capitalization of $720.24 million, a PE ratio of -10.03 and a beta of -0.52. Candel Therapeutics, Inc. has a one year low of $4.35 and a one year high of $11.36. The business’s fifty day moving average price is $8.35 and its 200-day moving average price is $6.50.

Candel Therapeutics (NASDAQ:CADL) last posted its earnings results on Thursday, May 14th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.16. On average, equities research analysts anticipate that Candel Therapeutics, Inc. will post -0.97 EPS for the current year.

Hedge Funds Weigh In On Candel Therapeutics

A number of institutional investors have recently added to or reduced their stakes in CADL. Vanguard Group Inc. raised its holdings in shares of Candel Therapeutics by 12.3% during the 3rd quarter. Vanguard Group Inc. now owns 2,007,112 shares of the company’s stock valued at $10,236,000 after buying an additional 219,563 shares in the last quarter. Geode Capital Management LLC lifted its position in Candel Therapeutics by 31.5% in the 2nd quarter. Geode Capital Management LLC now owns 903,970 shares of the company’s stock worth $4,575,000 after buying an additional 216,509 shares during the last quarter. Janus Henderson Group PLC purchased a new stake in Candel Therapeutics in the first quarter worth approximately $845,000. Halter Ferguson Financial Inc. boosted its stake in Candel Therapeutics by 20.9% in the first quarter. Halter Ferguson Financial Inc. now owns 904,051 shares of the company’s stock worth $4,430,000 after buying an additional 155,996 shares in the last quarter. Finally, Millennium Management LLC bought a new position in Candel Therapeutics during the third quarter valued at approximately $697,000. 13.93% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Citigroup dropped their price objective on Candel Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a report on Friday, March 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Candel Therapeutics in a report on Monday, April 20th. Wall Street Zen upgraded Candel Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, June 1st. Cantor Fitzgerald initiated coverage on shares of Candel Therapeutics in a report on Monday, April 20th. They issued an “overweight” rating on the stock. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $25.00 price target on shares of Candel Therapeutics in a report on Friday, March 13th. Six analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

About Candel Therapeutics

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.